Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

Biocon Biologics, a subsidiary of India-based Biocon Ltd, said on Thursday that U.S. FDA has approved Jobevne, a biosimilar ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold ...

The candidate in question is petrelintide, which the two companies will co-develop and co-commercialize with combination therapies, such as Roche’s GLP-1/GIP receptor dual agonist CT-388. Zealand will ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Investors and patients will have to wait sometime for such products to launch, however, with Zealand Pharma's CEO and President Adam Steensberg telling CNBC that he expects Petrelintide to come to ...